Choosing IXICO means partnering with a company entirely focussed on neuroscience with deep therapeutic and neuroimaging expertise across multiple neurodegenerative disease indications’
| Expert | Deep knowledge and extensive experience optimising neuroimaging biomarkers and imaging techniques for multi-center trials. |
| Innovative | Commitment to advancing imaging methodologies through ongoing research and development. |
| Compliant | Robust quality management processes compatible with national and international regulatory frameworks to deliver regulatorily compliant endpoints. |
| Collaborative | Strong ties with academic and industry leaders, fostering a collaborative approach to tackling the challenges of neurological disease research. |
| Attentive | Patient-centric site management that considers the specific access and comfort needs of neurological disease patients. |
IXICO has a strong track record in AD imaging analysis using advanced imaging biomarkers that quantify key AD measurements such as amyloid plaques, tau targets and brain atrophy, and a technology platform that provides accurate reproducible volumetric brain segmentations, in order to provide sponsors with cutting-edge assessment for drug safety, eligibility and efficacy.
With an established reputation in AD research, IXICO has been a key part of high-profile studies including the Bio-Hermes and AMYPAD initiatives and ongoing collaborations with leading organisations such as ADNI and EPAD.
| Quantitative Imaging Endpoints | Amyloid PET, Tau PET, Structural MRI, Vascular pathology, Arterial Spin Labelling (ASL) MRI, Diffusion MRI, Functional MRI, Quantitative Susceptibility Mapping |
| Neuroimaging Biomarker | Amyloid classification, Tau distribution, Segmentation volumes, Structural MRI (cross sectional and longitudinal), White matter hyperintensities (FLAIR), Diffusion MRI (Structural Connectivity Microstructural Integrity) Perfusion (cerebral blood flow), Functional MRI and Susceptibility. |
| PET Tracer Management & Coordination | Imaging site order management, tracer co-ordination and oversight, supply and transportation supply monitoring. |
IXICO excels in delivering HD imaging using advanced imaging biomarkers that quantify key HD measurements such as such as caudate nucleus and putamen atrophy, white matter tissue integrity changes and striatal susceptibility changes, together with the IXICO Platform that enhances the accuracy and efficiency of volumetric measurements.
With proven track record in HD clinical trials, and collaborations with key scientific institutions such as University College London (UCL) and the CHDI Foundation, IXICO’s combination of disease specific approaches, tools and technologies together with deep scientific expertise has enabled IXICO to build a reputation as the trusted partner for HD clinical trials.
| Quantitative Imaging Endpoints | Diffusion MRI (Tensor Imaging, Neurite Orientation Dispersion and Density Imaging, Free Water Imaging, Structural Connectivity), Magnetic Resonance Spectroscopy (MRS) for brain metabolic levels, Quantitative Susceptibility Mapping (QSM) to measure regional susceptibility, Functional Connectivity and Metabolism. |
| Neuroimaging Biomarker | Regional brain atrophy (Caudate Nucleus, Putamen, Whole Brain, Lateral Ventricles). |
IXICO provides core imaging measurement and analysis capabilities for MS clinical trials including lesion analysis, wider brain MRI assessment as well as spine and optic nerve structural MRI to enable sponsors to accurately assess drug safety, eligibility and efficacy.
| Lesion Analysis | lesion quantification tool embedded into the IXICO trial management and analytics platform to provide lesion identification, new lesions and/or assess lesion count, lesion stability and size/volume change(s). |
| Additional Quantitative Imaging Endpoints | Structural MRI for spinal cord, optic nerve analysis, Diffusion MRI, Functional MRI, Magnetic Resonance Spectroscopy (MRS) and Susceptibility. |
IXICO specializes in PD imaging providing advanced imaging biomarkers to quantify essential PD measurements such as dopamine transporter (DaT) density and brain atrophy for the assessment of drug safety, eligibility and efficacy.
IXICO has supported numerous brain scans collected through a variety of PD research initiatives, promoting innovation and harmonizing imaging data for better clinical trial outcomes. The IXICO Platform improves the accuracy and efficiency of volumetric measurements with PD-specific services: extensive imaging support with global site management, centralized radiology reads, PD-specific workflows, and advance bespoke image analytics.
Work with leading institutions and initiatives, for example C-Path CPP and tracer manufacturers such as GE underline IXICO’s expertise, ensures successful outcomes and contributes to IXICO’s position as a dependable partner helping to advance PD research and clinical trials.
| Dopamine transporter (DaT) imaging | including DaT SPECT, to assess dopamine transporter density in the brain, aiding in patient selection and trial eligibility. |
| Tracer-agnostic PET pipeline | supporting various tracers to measure dopaminergic function and neuroinflammation. |
| Quantitative Imaging Endpoints | Amyloid PET, Tau PET, Structural MRI, Vascular pathology, Quantitative Susceptibility Mapping (QSM), Diffusion MRI, Arterial Spin Labelling (ASL) MRI, Resting State fMRI (rs-fMRI) and Free Water imaging |
| Neuroimaging Biomarker Analysis | white matter changes, neuromelanin (see below), neuroinflammation. |
| Neuromelanin (NM) sensitive MRI imaging | emerging as a relevant measure (pigment found in dopamine neurons) for PD research in PD clinical trials which requires expert understanding of the practical and technical challenges in NM imaging, such as low spatial resolution and long acquisition times. |
In addition to imaging in MS, IXICO also specialize in MRI visual reads and image analysis in other demyelinating disorders such as MOG Antibody-Associated Disease (MOGAD).
MOGAD is an autoimmune disorder causing CNS inflammation, similar to MS but triggered by MOG antibodies, leading to vision and mobility issues. Lesions are often found in the optic nerve and spinal cord, with contrast-enhanced MRI being useful in detecting active inflammation
In addition to Parkinson’s Disease, IXICO also specialise in imaging in other Parkinsonian disorders such as Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA).
Imaging features can help differentiate PSP and MSA from Parkinson's disease, with distinct visually identifiable features such as in PSP where midbrain atrophy results in the Hummingbird appearance on axial T1 MRI images. Such features are identified by our team of expert neuroradiology readers during control centralised eligibility reads.
Volumetric MRI analysis can be used for quantitative assessment of regional atrophy, as well as functional PET and SPECT imaging playing a role in assessment of reduced dopamine transporter binding.
IXICO works across a number of rare neurological diseases, able to develop, optimise and apply advanced imaging and analytical techniques to produce disease focused imaging endpoints.
Example indications include: Spinocerebellar Ataxia (SCA), Friedreich's Ataxia (FA), Amyotrophic Lateral Sclerosis (ALS), and Cerebral Amyloid Angiopathy (CAA). In addition, IXICO’s analysis pipelines can also be optimised to paediatric populations.